UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 12, 2023

bluebird bio Inc

	(Exact name of Registrant as Specified in Its Charter)	
Delaware	001-35966	13-3680878
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
455 Grand Union Boulevard, Somerville, MA (Address of Principal Executive Offices)		02145 (Zip Code)
· , ,	(339) 499-9300 (Registrant's telephone number, including area code)	
	Not Applicable (Former Name or Former Address, if Changed Since Last Report)	
Check the appropriate box below if the Form 8-K filing is intended to s	simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

).4

- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- $Pre-commencement communications \ pursuant \ to \ Rule \ 14d-2(b) \ under \ the \ Exchange \ Act \ (17 \ CFR \ 240.14d-2(b))$
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered	
Common Stock, \$0.01 par value per share	BLUE	The Nasdaq Stock Market LLC	

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this

Emerging growth company \square

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. \Box

Item 7.01 Regulation FD Disclosure.

bluebird bio, Inc. (the "Company") will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on June 12, 2023. The Company plans to refer to the corporate slide deck attached as Exhibit 99.1 hereto during the presentation.

The information in this Current Report on Form 8-K pursuant to Item 7.01 is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to Item 7.01 of this Current Report.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit	
No.	Description
99.1	Corporate Update by bluebird bio, Inc.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 12, 2023 bluebird bio, Inc.

By: /s/ Joseph Vittiglio
Name: Joseph Vittiglio

Title: Chief Legal & Business Officer and Secretary





bluebird bio Company Presentation

June 2023

NASDAQ: BLUE

forward-looking statements

These slides and the accompanying oral presentation contain forward-looking statements and information. The use of words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "project," "intend," "future," "potential," or "continue," and other similar expressions are intended to identify forwardlooking statements. For example, all statements we make regarding our expectations regarding our programs and therapies, including but not limited to the timing or likelihood of regulatory filings, acceptance and approvals; our commercialization plans, including expansion of our QTC network; the ability of the Zynteglo to enable a seamless transition to commercializing lovo-cel; and the addressable markets for approved products and product candidates as well as statements relating to our finances and cash runway are forward looking. All forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we expected. These statements are also subject to a number of material risks and uncertainties that are described in our most recent quarterly report on Form 10-Q, as well as our subsequent filings with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.



Demonstrating gene therapy expertise

Clinical Leadership

180+ patients

treated with bluebird therapies across 8 clinical trials

Over 10+ years

of gene therapy research

Regulatory Success

Industry leader with 2 FDA approved gene therapies and 3rd BLA submitted to the FDA

Established track record for LVV technology, with 5 regulatory submissions

Commercial Impact

2 ongoing US launches, all with wholly-owned global rights


~22,000 patients

potentially addressable with our 3 programs in the U.S.1

Three established gene therapy programs

-	ZYNTEGLO® for beta-thalassemia	SKYSONA® for cerebral adrenoleukodystrophy	lovo-cel for sickle cell disease
Regulatory	FDA approved on August 17, 2022	FDA approved on September 16, 2022	BLA submitted April 2023
Clinical	 63 patients treated across all clinical trials 8 years of follow-up (n = 3) In Phase 3 studies (n=41) – 90% of patients achieved transfusion independence Safety profile generally consistent with that seen with cell collection and myeloablative conditioning 	 67 patients treated across all clinical trials Accelerated approval based on post-hoc analysis of 11 patients; estimated 72% likelihood of major functional disability free survival at 24 months Four boys treated in clinical trials developed hematologic malignancy; label includes boxed warning 	50 patients treated across all clinical trials 6 patients with ≥ 6 years of follow up In pivotal cohort (HGB-206 Group C, n=32), 96% experienced complete resolution of severe VOEs through 24 months of follow-up Safety profile generally consistent with that seen with cell collection, myeloablative conditioning and SCD
Commercial	 1,300–1,500 potentially eligible patients 7 patient starts since launch* 13 QTCs activated*; on track to scale to 40–50 QTCs by the end of 2023 	 40 potentially eligible patients 3 patient starts since launch*; anticipate 5–10 patient starts in 2023 3 QTCs activated*; 2 additional QTCs on the West Coast anticipated in 2023 	~20,000 potentially eligible patients Commercial launch expected in early 2024

^{*}As of May 9, 2023; Patient starts is defined as a cell collection (apheresis); Activated QTC defined as Qualified Treatment Center with a signed MSA



M NUMBER OF PATIENTS











ZYNTEGLO commercial launch off to a strong start

Launch built on three key pillars



Fit-for-purpose Qualified Treatment Center (QTC) network being activated in waves



*Graphic is illustrative and subject to change as final QTC network is determined; Activated QTC defined as Qualified Treatment Center with a signed MSA; Activated QTCs as of May 9, 202

QTC: Qualified Treatment Center

Confident in timely, quality access and reimbursement with upfront payment at \$2.8M price

PRICE TIED TO RECOGNIZED VALUE

Beta-thalassemia requiring regular RBC transfusions is associated with:

- \$6.4 million average lifetime medical care cost per patient¹
- 23X higher average total health care cost per patient per year vs. general population²
- Blood transfusions every 2-5 weeks for life³

SIMPLE AND INNOVATIVE PAYMENT STRATEGY

bluebird is offering payers:

- One-time upfront payment
- Outcomes-based agreement with up to 80% rebate if patient does not reach transfusion independence within 2 years
- Clinically-relevant outcome, easily tracked in claims data

ENCOURAGING PAYER INTERACTIONS

All target payers have responded favorably to approach:

- Estimated 70-75% of patients with beta-thalassemia have commercial insurance
- Engaging with state Medicaid agencies representing ~80% of publicly-insured betathalassemia patients

¹ Date on file ² Weiss et al. 2019 ³ TIF Guidelines

Early indications show value of ZYNTEGLO is recognized

Patients are achieving access

>190M

lives covered by a favorable coverage policy

2 weeks

on average for prior authorization approvals for drug product


ZERO

ultimate denials to date

ZYNTEGLO® manufacturing allows for flexible scheduling and is designed to deliver high quality drug product



ZYNTEGLO expected to enable seamless transition to commercializing lovo-cel for sickle cell disease



Opportunity to address a critical unmet need for >20,000 individuals living with severe sickle cell disease in the US



LARGE PATIENT POPULATION

- 1 in 365 Black or African American babies is born with sickle cell disease¹
- >20,000 SCD patients in the US may be addressed by gene therapy²

SIGNIFICANT UNMET NEED

- VOEs are the hallmark of SCD, but the disease is more than just pain
- 1 in 4 patients have a stroke by age 45³
- Widespread risk of organ damage or organ failure³
- 75% report difficulty completing daily tasks⁴

MEANINGFUL OPPORTUNITY

- Patients average \$4.0 million in direct medical costs, despite a median age of death of only 45⁵
- Approximately 65% report giving up a job due to SCD⁴
- Estimates of foregone income over a lifetime up to \$1.3 million⁶
- Nearly 1/3 report experiencing discrimination in a healthcare setting⁷

¹CDC ² Data on file³ Mortality Rates and Age at Death from Sickle Cell Disease: U.S., 1979–2005 ³ Kato GJ, Piel FB, Reid CD, et al. Sickle cell disease.
Nat Rev Dis Primers, 2018:4:18010. ⁴ Holdford et al 2021 ⁵ Gallagher ME et al. J Med Econ, 2022 Jan-Dec ⁶ Graf 2022 ⁷ Harvard Chan, RWJF Poll 2017.

lovo-cel BLA submitted in April 2023

Most robust and longest follow up of any gene therapy program for SCD


BLA includes:

- ✓ HGB-206 Group C as primary basis of effectiveness 36 patients with a median 32 months of followup and 2 patients in the HGB-210 study with 18 months of follow-up
- ✓ Pivotal study HGB-206; largest gene therapy study in SCD to date with clinically meaningful primary endpoint
- ✓ Safety data from 50 patients treated across the entire lovo-cel program with six patients with ≥ six years of follow-up



BLA: Biologics License Application

Planned 2023 network expansion ensures QTCs are in place and ready to treat appropriate SCD patients upon FDA approval of lovo-cel



*Graphic is illustrative and subject to change as final QTC network is determined; Activated QTC defined as Qualified Treatment Center with a signed MSA; Activated QTCs as of May 9, 2023






Launching now




- First commercial infusion has been completed; in total cell collection completed for three patients for SKYSONA
- Three activated QTCs
- Zero ultimate denials to date; payers recognize value and urgency to treat
- Anticipate 5-10 patient starts in 2023

Early, active cerebral adrenoles/udsystrophy refers to asymptomatic or mildly symptomatic (neurologic function score, MTS 5 1) boys who have gadelinium enhancement on brain imagenic resonance imaging (Mg) and Loes score of 0.5 9. SYSTOMA was garned accelerated approval based on 24-month Major Functional Disability (MPS) refers survival observed in clinical studies. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory rainful). Peak patients pitturelly, but they have not used our thrapies, CTC. Cualified Testament Cereful.



Strong financial position – cash burn and runway horizon



1. Cash blastice contains 5.5% in restricted cash restricted cash, we estimate our cash, cash equivalents and marketable securities as of March 31, 2023 will be sufficient to fund our operations into the second quarter of 2024. Cash Runway is cash, cash equivalents and marketable securities as of March 31, 2023 will be sufficient to fund our operations into the second quarter of 2024. Cash Runway is cash, cash equivalents and marketable securities as of March 31, 2023 will be sufficient to fund our operations into the second quarter of 2024. Cash Runway is cash, cash equivalents and marketable securities as of March 31, 2023 will be sufficient to fund our operations into the second quarter of 2024. Cash Runway is cash, cash equivalents and marketable securities as of March 31, 2023 will be sufficient to fund our operations into the second quarter of 2024. Cash Runway is cash, cash equivalents and marketable securities as of March 31, 2023 will be sufficient to fund our operations into the second quarter of 2024. Cash Runway is cash, cash equivalents and marketable securities as of March 31, 2023 will be sufficient to fund our operations into the second quarter of 2024. Cash Runway is cash equivalent to the second quarter of 2024. Cash Runway is cash equivalent to the second quarter of 2024. Cash Runway is cash equivalent to the second quarter of 2024. Cash Runway is cash equivalent to the second quarter of 2024. Cash Runway is cash equivalent to the second quarter of 2024. Cash Runway is cash equivalent to the second quarter of 2024. Cash Runway is cash equivalent to the second quarter of 2024. Cash Runway is cash equivalent to the second quarter of 2024. Cash Runway is cash equivalent to the second quarter of 2024. Cash Runway is cash equivalent to the second quarter of 2024. Cash Runway is cash equivalent to the second quarter of 2024. Cash Runway is cash equivalent to the second quarter of 2024. Cash Runway is cash equivalent to the second quarter of 2024. Cash Runway is cash equivalent to the second quarter

Upcoming milestones

First to market gene therapy for inherited hemoglobin disorders in the U.S.

SKYSONA® for cerebral adrenoleukodystrophy

- o Anticipate 5-10 patient starts in 2023
- Continued launch expansion throughout 2023

ZYNTEGLO® for beta-thalassemia

- First commercial revenue expected in Q2 2023
- Continued launch expansion throughout 2023
- o 40-50 QTCs by end of 2023

lovo-cel for sickle cell disease


- o Anticipate BLA acceptance in Q2 2023
- o Commercial launch expected early 2024

Proving our commercial model ->




Significant value driver -

bluebird bio: Setting the standard and proving the gene therapy commercial model



thank you

ZYNTEGLO® approval is underscored by impressive clinical study data




In Phase 3 studies presented at ASH 2022:

- 90% of patients achieved transfusion independence (TI) and normal or near-normal hemoglobin levels
- All patients who achieved TI remained transfusion free as of last follow-up
- Durable results with longest follow-up out to 5 years
- Results were consistent across ages and genotypes
- Majority of AEs and SAEs were consistent with myeloablative conditioning

Data as of July 2022

^{**}After a planned orthopedic surgery, the patient had blood loss, which required 1 packed red blood cell transfusion

lovo-cel: most advanced sickle cell disease gene therapy development program in the industry



^{*50} patients treated includes patients from HGB-205, HGB-206 Group A, Group B and Group C and HGB-210

Update on Pivotal Cohort (HGB 206 Group C) Presented at ASH 2022

- 96% experienced complete resolution of severe VOEs through 24 months of follow-up (ASH 2022)
- As of August 2022, 50 patients had been treated with lovo-cel, with up to 7 years of follow-up (median: 37.7 months)*
- Safety data remained consistent with the known side effects of autologous hematopoietic stem cell collection, myeloablative single-agent busulfan conditioning and underlying SCD
- As previously reported, patient with significant baseline SCD-related cardiopulmonary disease died >18 months post-infusion (considered unlikely to be related to lovo-cel).
- Updated data cut, including long-term followup submitted in BLA package

The approval of SKYSONA® was based on data from bluebird bio's Phase 2/3 study ALD-102 and Phase 3 study ALD-104

THE NEW ENGLAND JOURNAL of MEDICINE

October 4, 2017

ORIGINAL ARTICLE

Hematopoietic Stem-Cell Gene Therapy for Cerebral Adrenoleukodystrophy

Florian Esberg, M.D., Christine Dourcas, M.D., Patricia, L.Musolnos, M.D., Rivis, Paul J., Christoh, M.D., Seiton De Oliveron, M.D., Adrison, J. Hassehe, M.D., Myrian Kamarat, Filo, J., Colleno Disnereras, M.S. N., R.N., Teny C. Lond, M.D., Weston P. Miller, M.D., Gerald V. Spormond M.D., Earam Sankira, M.D., Amil, Shish, M.D., Caroline Soon, M.D., R.D., J.H., Bobby Gaspar, M.D., Paul Gissen, M.D., Herrand Amartines, M.D., Drogo Britolovic, M.D., Nicholas J.C. Smith, M.D., Aud'M. Paler, M.D., Esther Shamirt, M.P.H., Liras O'Menz, S.S., Dand'O'Landson, M.D., Patrick Audoney, M.D., J. Tars O'Menz, S.S., Dand'O'Landson, M.D., Patrick Audoney, M.D.

d (Assa) 2017, 277,1620, 1620

EFFICACY

FDA approval was based on a post hoc enrichment analysis of 24month improvement in major functional disability (MFD) free survival

SKYSONA treated patients (n = 11) had an estimated 72% likelihood of MFD-free survival at 24 months compared to untreated patients in a natural history study (n = 7) who had only an estimated 43% likelihood of MFD-free survival

A total of 67 patients were treated in clinical trials

SAFFTY

Four boys treated in clinical trials developed hematologic malignancy; label includes boxed warning

Other risks include serious infections, prolonged cytopenias, delayed platelet engraftment, risk of neutrophil engraftment failure, and hypersensitivity reactions.

Under accelerated approval, bluebird has agreed to provide confirmatory data to the $\ensuremath{\mathsf{FDA}}$

27

Early, a few cerebral ad-monthes/oxystrophyriconal (Septis 16 symptomatic (neurologic function score, NFS < 1) bow have a good invite mechanic memory to missing (MRI) and toes score of 0.5 9.5 XYSDIAN was granted accelerated approach for the incident of the score of 0.5 9.5 XYSDIAN was granted accelerated approach for the incident of the score of 0.5 9.5 XYSDIAN was granted accelerated approach for the incident of the score of 0.5 9.5 XYSDIAN was granted accelerated and of the score of 0.5 9.5 XYSDIAN was granted accelerated and 0.5 9.